Skip to main content

Advertisement

SpringerLink
Log in

Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′

  • Original article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

99mTc-DI-DD-3B6/22-80B3 (Thromboview, hereafter abbreviated to 99mTc-DI-80B3 Fab′) is a humanised, radiolabelled monoclonal antibody Fab′ fragment with high affinity and specificity for the D-dimer domain of cross-linked fibrin. The purpose of this study was to evaluate the safety, pharmacokinetics and dosimetry of four increasing doses of 99mTc-DI-80B3 Fab′ in healthy volunteers.

Methods

Thirty-two healthy volunteers (18–70 years; 16 male, 16 female) received a single intravenous injection of 0.5, 1.0, 2.0 or 4.0 mg of 99mTc-DI-80B3 Fab′. Safety outcomes (vital signs, electrocardiography, haematology, biochemistry, adverse events and development of human anti-human antibodies) were assessed up to 30 days post injection. Blood and urine samples were collected up to 48 h post injection. Gamma camera images were acquired at 0.5, 1, 2, 4, 6 and 24 h post injection. Dosimetry was performed using standard MIRD methodology.

Results

No adverse events considered to be drug related were observed. Human anti-human antibody was not detectable in any subject during the follow-up period. 99mTc-DI-80B3 Fab′ had a rapid initial plasma clearance (t 1/2α=1 h). The pharmacokinetic profile of the Fab′ fragment was generally linear across the four dose cohorts. By 24 h, 30–35% of the administered radioactivity appeared in the urine. There was marked renal accumulation with time, but no specific uptake was identified within other normal tissues. The effective dose was 9 mSv/750 MBq.

Conclusions

99mTc-DI-80B3 Fab’ is well tolerated, is rapidly cleared and exhibits clinically acceptable dosimetry—characteristics well suited to a potential thrombus imaging agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Douketis J, Kearon C, Bates, S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279:458–62

    Article  PubMed  CAS  Google Scholar 

  2. Tovey C, Wyatt S. Diagnosis, investigation, and management of deep vein thrombosis. BMJ 2003; 326:1180–4

    Article  PubMed  Google Scholar 

  3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Int Med 1998; 158:585–93

    Article  CAS  Google Scholar 

  4. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 Suppl 1:I4–8

    Article  PubMed  Google Scholar 

  5. Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med 2004; 351:268–77

    Article  PubMed  CAS  Google Scholar 

  6. Kearon C, Julian JA, Ginsberg JS. Noninvasive diagnosis of deep vein thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998; 128:663–77

    PubMed  CAS  Google Scholar 

  7. Kearon C. Diagnosis of pulmonary embolism. CMAJ 2003; 168:183–94

    PubMed  Google Scholar 

  8. Lisbona R, Derbekyan V, Novales-Diaz JA, Rush CL. Tc-99 m red blood cell venography in deep venous thrombosis of the lower limb: an overview. Clin Nucl Med 1985; 10:208–24

    Article  PubMed  CAS  Google Scholar 

  9. Lister-James J, Knight LC, Maurer AH, Bush LR, Moyer BR, Dean RT. Thrombus imaging with a technetium-99 m-labeled, activated platelet receptor-binding peptide. J Nucl Med 1996; 37:775–81

    PubMed  CAS  Google Scholar 

  10. Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, et al. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983; 31:767–78

    Article  PubMed  CAS  Google Scholar 

  11. Walker KZ, Milner LJ, Bautovich GJ, Borham P, Wood AK, Rylatt DB, et al. Detection of experimental thrombi in rabbits with an 131I-labeled fibrin-specific monoclonal antibody. Eur J Nucl Med 1990; 16:787–94

    Article  PubMed  CAS  Google Scholar 

  12. Walker KZ, Boniface GR, Phippard AF, Harewood W, Bautovich GJ, Bundesen PG. Preclinical evaluation of 99 m technetium-labeled DD-3B6/22 Fab’ for thrombus detection. Thromb Res 1991; 64:691–701

    Article  PubMed  CAS  Google Scholar 

  13. Bautovich G, Angelides S, Lee FT, Greenough R, Bundesen P, Murray P, et al. Detection of deep venous thrombi and pulmonary embolus with technetium-99 m-DD-3B6/22 anti-fibrin monoclonal antibody Fab’ fragment. J Nucl Med 1994; 35:195–202

    PubMed  CAS  Google Scholar 

  14. Morris TA, Marsh JJ, Chiles PG, Konopka RG, Pedersen CA, Schmidt PF, et al. Single photon emission computed tomography of pulmonary emboli and venous thrombi using anti-D-dimer. Am J Respir Crit Care Med 2004; 169:987–93

    Article  PubMed  Google Scholar 

  15. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40 Suppl:37–61

    Google Scholar 

  16. McKay E. A software tool for specifying voxel models for dosimetry estimation. Cancer Biother Radiopharm 2003; 18: 379–92

    Article  PubMed  Google Scholar 

  17. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538–46

    PubMed  CAS  Google Scholar 

  18. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34:689–94

    PubMed  CAS  Google Scholar 

  19. Shen S, DeNardo GL, Sgouros G, O’Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 1999; 40:2102–6

    PubMed  CAS  Google Scholar 

  20. Oster ZH, Som P. Of monoclonal antibodies and thrombus-specific imaging [editorial]. J Nucl Med 1990; 31:1055–8

    PubMed  CAS  Google Scholar 

  21. Lee FT, Milner LJ, Boniface, GR, Bautovich GJ, Weedon AR, Bundesen PG, et al. Evaluation of thrombus detection in a rabbit model using a technetium-99 m-labeled antifibrin monoclonal antibody. Immunol Cell Biol 1992; 70:173–9

    Article  PubMed  CAS  Google Scholar 

  22. Ciavolella M, Tavolaro R, Di Loreto M, La Torre F, Nicolai A, Schillaci O, et al. Immunoscintigraphy of venous thrombi: clinical effectiveness of a new antifibrin D-dimer monoclonal antibody. Angiology 1999; 50:103–9

    Article  PubMed  CAS  Google Scholar 

  23. Schaible T, DeWoody K, Weisman H, et al. Accurate diagnosis of acute deep venous thrombosis with technetium-99 m antifebrin scintigraphy: Final Phase III trial results [abstract]. J Nucl Med 1992;33:848

    Google Scholar 

  24. Behr T, Becker W, Hannappel E, Goldenberg DM, Wolf F. Targeting of liver metastases of colorectal cancer with IgG, F(ab’)2, and Fab’ anti-carcinoembryonic antigen antibodies labeled with 99 mTc: the role of metabolism and kinetics. Cancer Res 1995; 55 Suppl:5777–85

    Google Scholar 

  25. Schaible TF, Alavi A. Antifibrin scintigraphy in the diagnostic evaluation of acute deep venous thrombosis. Semin Nucl Med 1991; 21:313–24

    Article  PubMed  CAS  Google Scholar 

  26. Morris TA, Marsh JJ, Konopka R, Pedersen AS, Chiles PG, Fagnani R, et al. Antibodies against the fibrin β-chain amino-terminus detect active canine venous thrombi. Circulation 1997; 96:3173–9

    PubMed  CAS  Google Scholar 

  27. Hirsch J, Gallus AS. 125-I-labeled fibrinogen scanning. Use in the diagnosis of venous thromboembolism. JAMA 1975; 233:970–3

    Article  PubMed  Google Scholar 

  28. Sautter RD, Larson DE, Bhattacharyya SK, Chen HM, Treuhaft PS, Milbauer JP, et al. The limited utility of fibrinogen I-125 leg scanning. Ach Int Med 1979; 139:148–53

    Article  CAS  Google Scholar 

  29. Robertson PL, Berlangieri SU, Goergen SK, Waugh JR, Kalff V, Steven SN, et al. Comparison of ultrasound and blood pool scintigraphy in the diagnosis of lower limb deep venous thrombosis. Clin Radiol 1994; 49:382–90

    Article  PubMed  CAS  Google Scholar 

  30. Koblik PD, De Nardo GL, Berger HJ. Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism. Semin Nucl Med 1989; 19:221–37

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a competitive, peer-reviewed R&D START grant (AusIndustry, Commonwealth Government, Australia) and a research grant from AGEN Biomedical Limited (Acacia Ridge, Queensland, Australia 4110). The authors acknowledge the independent technical editing service provided by ProScribe Medical Communications funded in part by an unrestricted financial grant from AGEN Biomedical Limited. In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, AGEN did not impose any impediment, directly or indirectly, on the publication of the study’s results. Dr. Macfarlane was the principal investigator during the study. Dr. Macfarlane currently acts as a consultant to AGEN Biomedical Limited for product and protocol development. Professor Eisenberg is also a consultant to AGEN Biomedical Limited and Dr. Gerometta is an employee of AGEN Biomedical Limited. Wendy Tsui is employed by the University of New South Wales under a research contract between AGEN Biomedical Limited and the University. We would like to acknowledge Q-Pharm staff for assisting with the conduct of the study.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Royal Brisbane and Women’s Hospital,, Brisbane, Australia

    David J. Macfarlane

  2. Department of Nuclear Medicine, St George Hospital,, Sydney, Australia

    Richard C. Smart & Wendy W. Tsui

  3. School of Medicine, University of New South Wales,, Sydney, Australia

    Wendy W. Tsui

  4. Research and Development, AGEN Biomedical Limited,, Brisbane, Australia

    Michael Gerometta

  5. Lilly Research Laboratories, Eli Lilly Company,, Indianapolis, USA

    Paul R. Eisenberg

  6. Centre for PET, Austin Health, Melbourne, Australia

    Andrew M. Scott

  7. Ludwig Institute for Cancer Research,, Melbourne, Australia

    Andrew M. Scott

Authors
  1. David J. Macfarlane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard C. Smart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wendy W. Tsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Gerometta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul R. Eisenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrew M. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Macfarlane.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Macfarlane, D.J., Smart, R.C., Tsui, W.W. et al. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′. Eur J Nucl Med Mol Imaging 33, 648–656 (2006). https://doi.org/10.1007/s00259-005-0025-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-0025-y

Keywords

Search

Navigation